Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8311603 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL9486743 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL4523110 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL8311599 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL7811433 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL1686983 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL22582139 | 0.96 | USP2 (0.31) | USP2ESR1KDM4E | |
| SCHEMBL16673765 | 0.77 | — | — | |
| SCHEMBL19486294 | 0.74 | — | — | |
| SCHEMBL9470709 | 0.74 | USP2 (0.37) | USP2ESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11565999-B2 | Methods of synthesizing aztreonam derivatives | ARIXA PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | claimed |
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | claimed |
| WO-2020219258-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| CN-102127068-B | Method for synthesizing aztreonam compound | SHANXI POWERDONE PHARMACEUTICS CO LTD | 2012-08-29 | — | — | CN | claimed |
| CN-102127068-A | Method for synthesizing aztreonam compound | SHANXI POWERDONE PHARMACEUTICS CO LTD | 2011-07-20 | — | — | CN | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-108368040-B | Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11565999-B2 | Methods of synthesizing aztreonam derivatives | ARIXA PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11565999-B2 | Methods of synthesizing aztreonam derivatives | ARIXA PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020219258-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-1012139-A1 | AZETIDINONE DERIVATIVES AS $g(b)-LACTAMASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999010324-A1 | AZETIDINONE DERIVATIVES AS β-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 1999-03-04 | — | — | WO | disclosed |
| US-5254681-A | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1993-10-19 | — | — | US | disclosed |
| EP-0411541-A2 | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-02-06 | — | — | EP | disclosed |
| EP-0127541-B1 | SALTS OF AMINO-BETA-LACTAMIC ACIDS AND PROCESS FOR THE PREPARATION THEREOF | GEMA S.A. (ES) | 1990-08-01 | — | — | EP | disclosed |
| US-4659814-A | Salts of amino-beta-lactamic acids and process for the preparation thereof | GEMA, S.A. (ES) | 1987-04-21 | — | — | US | disclosed |
| US-4515789-A | BACTERICIDES PRESERVATIVES, GROWTH PROMOTERS | BAYER AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
| EP-0127541-A2 | Salts of amino-beta-lactamic acids and process for the preparation thereof | GEMA S.A. (ES) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | DTYMK, TYMS, TYMP | FAP 4141/4885USP2 2913/4885ESR1 3282/4885 |
| US-11565999-B2 | Methods of synthesizing aztreonam derivatives | DTYMK, TYMS, TYMP | FAP 4141/4885USP2 2913/4885ESR1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.